Table of contents

1 Definition, nomenclature, and classification of antiresorptive drug-related osteonecrosis of the jaw (ARONJ)

Tae-Geon Kwon

- When was bone necrosis first reported and how is it defined?
- What definitions for antiresorptive drug-related osteonecrosis of the jaw (ARONJ) exist?
- Why are different terms used and why are there so many?
- · How is ARONJ classified?
- Clinical features of antiresorptive drug-related osteonecrosis of the jaw
 Morten Schiodt, Bente Brokstad Herlofson
 - · How do we take a medical history based on relevant factors?
 - How do we diagnose and classify nonexposed osteonecrosis?
 - How do we avoid misdiagnosing common dental infections like apical periodontal processes as nonexposed antiresorptive drug-related osteonecrosis of the jaw (ARONJ)?
 - Is the development of ARONJ spontaneous or caused by a preceding trauma or dental procedure?
 - What is the difference between ARONJ, osteomyelitis (OM), and osteoradionecrosis (ORN)?
- Imaging modalities for antiresorptive drug-related osteonecrosis of the jaw
 Kenneth E Fleisher, King Chong Chan, Niloufar Amintavakoli
 - Which imaging modalities are used for the diagnosis of antiresorptive drug-related osteonecrosis of the jaw (ARONJ)?
 - What are the advantages and disadvantages of each imaging modality?
 - What are the radiographic findings for ARONJ?
 - · What is meant by metabolic changes for ARONJ lesions?

4 Treatment and outcomes measures for antiresorptive drug-related osteonecrosis of the jaw

Oliver Ristow, Alberto Bedogni, Stefano Fedele

- What are the real aims of treatment for antiresorptive drug-related osteonecrosis of the jaw (ARONJ)?
- What are relevant outcomes measures for the treatment of ARON 12
- · What is the impact of definition and staging for ARONJ?
- · What therapeutic strategies exist for ARONJ?
- 5 Risk factors for antiresorptive drug-related osteonecrosis of the jaw

Robert E Marx

- What are the real risk factors for antiresorptive drug-related osteonecrosis of the jaw (ARONJ)?
- · What are the initiation factors for ARONJ?
- · Where are the vulnerable sites?
- What are the relevant comorbidities?
- 6 Pathogenesis of antiresorptive drug-related osteonecrosis of the jaw

Riham Fliefel, Sven Otto

- Which theories exist for the pathogenesis of antiresorptive drug-related osteonecrosis of the jaw (ARONJ)?
- Why are the jaw bones predominantly affected?
- Why can nitrogen-containing bisphosphonates and denosumab cause ARONJ?



29

39

45

Small animal models for antiresorptive drug-related osteonecrosis of the jaw James L Borke, Ezher H Dayisoylu, Stephan Zeiter

- · Does small animal investigation make sense?
- What are the opportunities and limitations of small animal investigation?
- What are the advantages and disadvantages of small animal models of antiresorptive drug-related osteonecrosis of the jaw (ARONJ)?
- What controversies exist concerning these small animal models?
- Are there significant differences among the various small animal models of ARONJ?
- · Does jaw size matter?
- 8 Large animal models for antiresorptive drug-related osteonecrosis of the jaw
 59 Matthew R Allen, Pit Voss, Christoph Pautke
 - Can antiresorptive drug-related osteonecrosis of the jaw (ARONJ) be related in large animals?
 - · Are animal models really necessary?
 - What are the advantages of using large animals versus rodents?